Results 181 to 190 of about 32,248 (253)

Abstracts

open access: yesMolecular Oncology, Volume 20, Issue S1, Page 1-692, August 2026.
Abstracts submitted to the ‘EACR 2026 Congress: Innovative Cancer Science’, from 08–11 June 2026 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

Management of Advanced Prostate Cancer in the Asia‐Pacific Region: Summary of the Asia‐Pacific Advanced Prostate Cancer Symposium 2025

open access: yesAsia-Pacific Journal of Clinical Oncology, Volume 22, Issue 4, Page 546-556, August 2026.
Summary of the Asia Pacific Advanced Prostate Cancer Symposium 2025, showing disciplines and diversity of participants, discussion topics (high‐risk localized/locally advanced prostate cancer; PSA persistence and recurrence; radioligand therapy; genetics and genomics; bone protection and other aspects of supportive care), key themes, and high‐level ...
Edmund Chiong   +28 more
wiley   +1 more source

Identification of drug repurposing candidates for the treatment of polycystic kidney disease

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 16, Page 5082-5101, August 2026.
Background and Purpose Autosomal dominant polycystic kidney disease (ADPKD) is a leading cause of end‐stage renal disease with limited treatment options. Drug repurposing offers a promising strategy to find effective treatments. Experimental Approach We identified birinapant, bardoxolone methyl and salicylic acid as repurposing candidates for ADPKD and
Alina Meyer   +9 more
wiley   +1 more source

MAPK Inhibitor‐Tolerant Persister Cells in Melanoma: Mechanisms and Therapeutic Vulnerabilities

open access: yesCancer Science, Volume 117, Issue 8, Page 2050-2063, August 2026.
Melanoma response to MAPK inhibition progresses from drug‐sensitive cells to drug‐tolerant persister states, which enable survival through adaptive signaling, metabolic rewiring, and phenotypic plasticity. These persister cells serve as an intermediate reservoir from which resistant tumors ultimately emerge. ABSTRACT Though major advancements have been
Bhoomi Shah   +3 more
wiley   +1 more source

Mechanisms of Therapeutic Resistance and Recent Advances in Glioblastoma Treatment

open access: yesImmunology &Cell Biology, Volume 104, Issue 7, Page 711-728, August 2026.
Three interconnected processes in glioblastoma (GBM) biology: initiation, stratification, and immunosuppression. 1) Initiation: GBM initiation is proposed to occur through migration of TERT mutation‐bearing neural stem cells from the subventricular zone to the frontal and temporal cortices, where a subsequent oncogenic transformation drives their ...
Emerson Achari   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy